

# 1    **The potential health impact and healthcare cost savings of** 2    **different sodium reduction strategies in Canada**

3  
4    Nadia Flexner<sup>1\*</sup>, Amanda C. Jones<sup>2</sup>, Ben Amies-Cull<sup>3</sup>, Linda Cobiac<sup>4</sup>, Eduardo Nilson<sup>5,6</sup>, Mary  
5    R. L'Abbe<sup>1\*</sup>

6  
<sup>1</sup>Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.

<sup>2</sup>Department of Public Health, University of Otago, Wellington, New Zealand.

<sup>3</sup>Nuffield Department of Primary Care Healthcare Sciences, University of Oxford, Oxford, United Kingdom.

<sup>4</sup>Griffith University, Queensland, Australia.

<sup>5</sup>Center for Epidemiological Research in Nutrition and Public Health, University of São Paulo, São Paulo, Brazil.

<sup>6</sup>Oswaldo Cruz Foundation (Fiocruz/Brasilia), Brasilia, Brazil.

\*Corresponding authors: [mary.labbe@utoronto.ca](mailto:mary.labbe@utoronto.ca); [nadia.flexner@mail.utoronto.ca](mailto:nadia.flexner@mail.utoronto.ca)

7    **Keywords:** sodium reduction, health impact, cardiovascular disease, cost-utility analysis, multi-  
8    state lifetable model, food policy.

## 9 10    **Abstract**

### 11    **Background**

12    High dietary sodium is the main dietary risk factor for non-communicable diseases due to its  
13    impact on cardiovascular diseases, the leading cause of death globally. The Government of  
14    Canada has taken measures to reduce average dietary sodium intakes, such as setting voluntary  
15    sodium reduction targets for packaged foods and recently approving regulations mandating 'high  
16    in' front-of-pack labeling (FOPL) symbols.

### 17    **Objectives**

18 To estimate the number of avoidable ischemic heart disease (IHD) and stroke incidence cases,  
19 and their associated healthcare cost and Quality-Adjusted Life Year (QALY) savings resulting  
20 from different sodium reduction strategies and recommendations in Canada.

## 21 **Methods**

22 We used the PRIMETIME model, a proportional multi-state lifetable model. Outcomes were  
23 modeled over the lifetime of the population alive in 2019, at a 1.5% discount rate, and from the  
24 public healthcare system perspective. Nationally representative data were used as inputs for the  
25 model.

## 26 **Results**

27 Fully meeting Health Canada's sodium reduction targets was estimated to prevent 219,490 (95%  
28 UI, 73,409–408,630) cases of IHD, and 164,435 (95% UI, 56,121–305,770) strokes. This led to a  
29 gain of 276,185 (95% UI, 85,414–552,616) QALYs, and healthcare costs savings of CAD\$  
30 4,212 (95% UI, 1,303–8,206) million over the lifetime of the 2019 cohort. Sodium reduction  
31 intake through FOPL regulations has the potential to prevent between 35,930 (95% UI, 8,058–  
32 80,528) and 124,744 (95% UI, 40,125–235,643) cases of IHD, and between 26,869 (95% UI,  
33 5,235–61,621) and 93,129 (95% UI, 30,296–176,014) strokes. This results in QALY gains  
34 ranging from 45,492 (95% UI, 10,281–106,579) to 157,628 (95% UI, 46,701–320,622), and  
35 healthcare costs savings ranging from CAD\$ 695 (95% UI, 160–1,580) to CAD\$ 2,415 (95% UI,  
36 722–4,746) million over the lifetime of the 2019 Canadian cohort. Greater health and healthcare  
37 costs gains were estimated if Canadians were to meet the population-level sodium intake

38 recommendations of the World Health Organization (2,000 mg/day) and the Adequate Intake  
39 recommendation (1,500 mg/day). All sodium reduction strategies tested were cost saving.

#### 40 **Conclusions**

41 Reducing population-level sodium intakes is feasible and has the potential to improve health  
42 outcomes and save healthcare costs in Canada. From interventions tested, most health and  
43 healthcare costs gains were attributed to fully meeting sodium reduction targets, which highlights  
44 the importance of changing the voluntary nature of these targets to mandatory. A combination of  
45 strategies, mandatory sodium reduction targets and implementation of the ‘high in’ FOPL  
46 symbol would provide the most benefit from a public health standpoint.

## 47 **1. Introduction**

48 Diets high in sodium are the main dietary risk factor for non-communicable diseases (NCDs)(1)  
49 due to their impact on cardiovascular diseases (CVDs)(2, 3), the leading cause of death globally  
50 and a major contributor to disability, particularly in relation to diseases such as ischemic heart  
51 disease (IHD) and stroke(4). In Canada, CVDs (mostly IHD and strokes) rank as the second  
52 leading cause of death (after cancers), accounting for 25% of all deaths each year(5). The World  
53 Health Organization (WHO) broadly considers reducing population-level dietary sodium intake  
54 to be a cost-effective measure that could save many lives by decreasing and preventing the  
55 burden of diet-related NCDs, mainly from CVDs, and save costs in the long run(6, 7).

56 The WHO recommends consuming less than 2,000 mg/day of sodium (5 g/day of salt)(8);  
57 however, intake levels around the world largely exceed recommendations(8). Canada is not an  
58 exception, as recent sodium intake estimations showed that Canadians consume an average of  
59 2,760 mg/day of sodium(9, 10), with 63.9% of Canadian adults exceeding the recommendation  
60 for Chronic Disease Risk Reduction (CDRR) levels (2,300 mg/day) and only 9.4% of Canadian  
61 adults meeting the Adequate Intake (AI) levels (1,500 mg/day)<sup>10</sup>.

62 Reducing sodium intake is a WHO ‘best buy’ recommendation for the prevention and control of  
63 NCDs(6). In its *SHAKE Technical Package for Salt Reduction*(11), WHO recommends ideally  
64 implementing a joint combination of measures to reduce population-level sodium intakes. These  
65 measures include monitoring salt use (e.g., intakes, salt content in foods), promote food  
66 reformulation to contain less salt by setting salt targets levels in foods, adopting interpretive  
67 front-of-pack labeling systems, and restricting marketing of foods ‘high in’ salt, among  
68 others(11).

69 The Canadian government has implemented and adopted several evidence-based policies to  
70 make the healthier choice easier for all Canadians, as described in the *Canadian Healthy Eating*  
71 *Strategy* (2016)(12). As part of this comprehensive strategy, Health Canada committed to  
72 ongoing collaboration with stakeholders in the food industry to reduce sodium levels in packaged  
73 foods through updating the voluntary sodium reduction targets for processed foods (2020-  
74 2025)(13). It is worth noting that progress evaluations of the previous (2012-2016) set of  
75 voluntary sodium reduction targets have only shown modest results(14), and only minor  
76 revisions have been made to the latest set of targets (2020-2025)(13). In addition, Health Canada  
77 recently approved front-of-pack labeling (FOPL) regulations that will require packaged foods  
78 that meet or exceed established thresholds for nutrients-of-concern, including sodium, to display  
79 a ‘high in’ FOPL nutrition symbol, to come into effect by January 2026(15).

80 Estimating the impact of public health policies, such as the aforementioned, could be challenging  
81 or simply not feasible using traditional epidemiological research methods such as cohort studies,  
82 randomized control trials or natural experiments. Policy scenario modeling has proven to be an  
83 appropriate and strategic tool for estimating the health and economic impact of public health  
84 policies prior to actual implementation(16). Specifically, NCD policy scenario modeling allows  
85 us to predict the cumulative health outcomes of interventions over the long term and across the  
86 entire population; in addition to providing evidence on what the magnitude would be to take  
87 action or not by comparing different policy scenarios with a ‘business as usual’ scenario(17).

88 A systematic review of previous policy scenario modeling studies have demonstrated the cost-  
89 effectiveness of reducing dietary sodium intake(18). Studies in the Canadian context have  
90 estimated the economic and health impact of reducing sodium intake to recommended levels  
91 when compared to previous sodium intake levels (i.e., 3,800 mg/day) using data from CCHS-

92 Nutrition 2004(19). More recently, using data from CCHS-Nutrition 2015, we previously  
93 estimated the number of CVDs deaths that could be averted or delayed if Canadians were to  
94 reduce their sodium intake to recommended levels(10, 19), and as a result of implementing ‘high  
95 in’ FOPL regulations(20, 21). However, to the best of our knowledge, no study in Canada has  
96 previously estimated the health impact and healthcare cost savings from ‘real world’ policy  
97 scenario options to reduce population level dietary sodium intakes (i.e., food reformulation and  
98 mandatory ‘high in’ FOPL symbol).

99 In this study, we aimed to provide policymakers and stakeholders with evidence supporting  
100 policy options to reduce excess dietary sodium intakes in Canada. We estimated the number of  
101 avoidable ischemic heart disease and stroke incidence cases, and their associated healthcare cost,  
102 and Quality-Adjusted Life Year (QALY) savings resulting from 1) meeting sodium intake  
103 recommended levels, 2) meeting sodium reduction targets for packaged foods established by  
104 Health Canada, and 3) implementing ‘high in’ front-of-pack labeling regulations in Canada.

## 105 **2. Materials and methods**

106 We conducted a cost-utility analysis using a public healthcare system perspective. The potential  
107 health and healthcare costs impact of reducing dietary sodium intake were modelled by  
108 comparing ten counterfactual scenarios (described below in section ‘*Counterfactual scenarios*  
109 *modeled*’) to a ‘business as usual’ or ‘baseline’ scenario. Outcomes were modeled over the  
110 lifetime of the Canadian population alive in 2019, and a 1.5% discount rate was applied to both  
111 health gains and healthcare costs, as recommended by the Canadian Agency for Drugs and  
112 Technologies in Health (CADTH)(22).

## 113 *2.1 PRIMETIME model: a proportional multi-state lifetable model*

114 The PRIMETIME model, an established and robust proportional multi-state lifetable model, was  
115 used in this study(23, 24). PRIMETIME is an epidemiological model tool, developed by  
116 researchers at the University of Oxford, that has been widely applied to a range of different diet  
117 and obesity policy scenarios in the UK and other countries(24-31). This model has been designed  
118 for policy scenario evaluation and can be utilized to assess future effects of policies in order to  
119 help policymakers set priorities for action. In a world of limited resources, governments are  
120 increasingly required to properly assess the cost-effectiveness of interventions to strategically  
121 allocate their resources. The PRIMETIME model is a tool for policy support and prioritization that  
122 under the same set of assumptions can help compare different policy options by assessing the  
123 cost-effectiveness of interventions.

124 The PRIMETIME model is comprised of the following interconnected modules: a risk factor  
125 exposure module, a series of disease models, and a lifetable. Detailed methods of the model have  
126 been published elsewhere(24). Briefly, PRIMETIME uses epidemiological data collected mainly  
127 from meta-analyses of randomized control trials or prospective cohort studies to parameterize the  
128 relationships between risk factors and NCDs. This can be modeled as direct effects of risk factors  
129 or via their intermediate risk factors (i.e., blood pressure, BMI, or total cholesterol), where  
130 appropriate. The Canadian PRIMETIME Salt model includes the two main CVDs associated with  
131 high consumption of salt/sodium, IHD and stroke. These diseases are modeled in PRIMETIME in  
132 a three-state Markov model in which the population is either in a disease-free state, a diseased  
133 state, or dead. Then, the lifetable combines these simulated changes in population health and  
134 healthcare system as a result of changes in disease epidemiology.

135 We adapted the PRIMETIME model to the Canadian context by collecting, processing, and  
136 analyzing Canadian-specific and nationally representative data (i.e., dietary sodium intakes,  
137 population demographics, disease epidemiology and healthcare costs). **Table 1** shows the data  
138 sources used as inputs for the PRIMETIME model in Canada. A closed cohort analyses was  
139 performed, taking the Canadian adult population as a baseline ( $\geq 19$  y) over the lifetime of the  
140 cohort or until they reach 100y of age.

## 141 *2.2 Model input parameters*

### 142 *Population inputs*

143 Canadian population size and all-cause mortality data by 1-year age/sex groups were included in  
144 the model. Data was obtained from the publicly available Statistics Canada CANSIM tables for  
145 the year 2019 (**Table 1, Supplementary Table S1**). All-cause mortality data was only available  
146 in 5-year age/sex groups; thus, further processing was required. Data was interpolated to 1-year  
147 using a temporal disaggregation method(32).

### 148 *Disease epidemiology*

149 Data on incidence, prevalence and disease-specific mortality were collected for ischemic heart  
150 disease and stroke for the year 2019 (**Table 1**). First, we prioritized alignment of WHO  
151 International Statistical Classification of Diseases and Related Health Problems 10th Revision  
152 (ICD-10) codes(33) between disease epidemiology and healthcare cost data (described below).  
153 Disease epidemiology data was only available in 5y age/sex groups up to age 90+ for all  
154 parameters; thus, further processing was required. Data was extrapolated to age 100+ using a  
155 polynomial trend line (**Supplementary Table S2**). Then, health data estimates were interpolated



156 to 1y age/sex groups using a temporal disaggregation method to obtain smooth disaggregated  
157 counts, while maintaining the aggregated total(32).

158 Case fatality rates were derived from cause-specific incidence, prevalence and mortality data,  
159 together with population size using a Bayesian approach, the *disbayes* optimization method built  
160 on the Stan software (*disbayes* package available in R)(32, 34). It was assumed that case fatality  
161 was constant for all ages below 35. The *disbayes* package estimates case fatality using a three-  
162 state transition process of disease free, disease, or death. The *disbayes* ' approach and  
163 assumptions are consistent with the ones underpinning disease simulation in the PRIMEtime  
164 model (**Supplementary Table S1**).

165 Mean systolic blood pressure (SBP) estimates for the year 2019 were acquired. Data was  
166 available by sex (male, female) and age group (6-11 years, 12-19, 20-39, 40-59, 60-79) (**Table**  
167 **1**). As SBP measurements were not available for individuals aged 80 years and older, we  
168 assumed the same values as those observed for 60-79 years age/sex groups for individuals in the  
169 80+ years group.

### 170 *Dietary sodium intake*

171 This study used data from the Canadian Community Health Survey (CCHS)-Nutrition 2015 to  
172 estimate baseline and counterfactual dietary sodium intakes for Canadian adults ( $\geq 19$  y). CCHS-  
173 Nutrition 2015 is a nationally representative, cross-sectional health and nutrition survey that  
174 utilized 24-hour (24h) dietary recalls to collect data on food and beverage intake across the 10  
175 Provinces of Canada (aged 1y or older)(35). We used both available days of 24h dietary recalls  
176 to estimate usual dietary sodium intakes for adults by Dietary Reference Intakes (DRI)(36)

177 age/sex groups (i.e., males and females ages 19-30, 31-50, 51-70, 71+), methods that have been  
178 previously published by our research group(10, 20, 21).

179 *Counterfactual scenarios modeled*

180 *Meeting sodium intake recommended levels (Scenarios 1 and 2)*

181 We modeled potential health and healthcare costs gains from meeting WHO sodium intake  
182 recommendations of 2,000 mg/day and the AI recommendations of 1,500 mg/day. The  
183 proportion needed to meet these recommendations from the current sodium intakes (2,758  
184 mg/day) was calculated and applied to each DRI age/sex group to build our counterfactual  
185 scenarios<sup>10</sup> (**Table 2, Supplementary Table S3**).

186 *Meeting sodium reduction targets established by Health Canada (Scenario 3)*

187 Fully meeting Health Canada’s voluntary sodium reduction targets for packaged foods was used  
188 as one of the counterfactual scenarios tested in this study. Our research group has previously  
189 published methods for this policy modeling approach(10, 37). Briefly, data from a Canadian  
190 branded packaged food composition database, the University of Toronto’s Food Label  
191 Information and Price database (FLIP 2017), was linked to the Food and Ingredient Details (FID)  
192 file in the CCHS-Nutrition 24-hour recall to estimate baseline and counterfactual dietary sodium  
193 intakes. The counterfactual scenario was estimated after conducting a systematic ‘reformulation’  
194 of eligible packaged foods to meet Health Canada’s sodium reduction targets<sup>10</sup> (**Table 2,**  
195 **Supplementary Table S3**).

196 *Implementing ‘high in’ front-of-pack labeling regulations (Scenarios 4-10)*

197 Based on recent FOPL evidence from observational and experimental studies(38-40), we  
198 estimated potential changes to dietary sodium intakes(20). These studies estimated changes in  
199 the content of nutrients of public health concern (i.e., saturated fats, sodium, and sugars) in food  
200 and beverage purchases when a ‘high in’ FOPL was in place. We assumed that changes observed  
201 in food and beverage purchases would carry over to dietary intakes, as evidence suggests that  
202 documented food purchases can serve as a reasonably precise estimate of overall diet quality(41).  
203 We modeled changes in overall food and beverage sodium content based on early evaluations of  
204 the Chilean Food Labeling and Marketing Law (-4.7%)(38) (*Scenario 4*), the criteria used by  
205 WHO to estimate FOPL cost-effectiveness as part of the *Technical briefing for Appendix 3 of the*  
206 *Global Action Plan for NCDs* (-6.4%)(40) (*Scenario 5*), and a FOPL systematic review and  
207 network meta-analysis (-7.8%)(39) (*Scenario 6*), (**Table 2, Supplementary Table S3**).

208 Furthermore, we constructed counterfactual scenarios using data from consumer research  
209 reporting the proportion of consumers that choose or were willing to choose products with fewer  
210 ‘high in’ FOPL symbols(42-47). We first identified foods and beverages in FLIP 2017 similar to  
211 those reported in CCHS-Nutrition 2015 that would display at least one fewer ‘high in’ FOPL  
212 symbol for nutrients of concern, including sodium. Then, to estimate ‘new’ dietary intakes, we  
213 replaced nutritional values of identified foods for a random sample of 30%, 50%, and 70% of  
214 *CCHS-Nutrition* adult participants that consume at least one food that would display a ‘high in’  
215 symbol (*Scenarios 7-9*). Additionally, to estimate the potential maximum effect of FOPL, we  
216 simulated changes for all adult participants (*Scenario 10*) (**Table 2, Supplementary Table S3**).

217 All FOPL counterfactual scenarios tested in this study are based on ‘high in’ FOPL evidence,  
218 which is the FOPL system recently approved in Canada. We have previously published methods

219 for all FOPL policy scenarios(20, 21). For this study, we used potential impacts of implementing  
220 FOPL only for changes in sodium intakes.

### 221 *Direct healthcare costs*

222 This study followed the perspective of the public healthcare system. The model estimated direct  
223 healthcare cost differences between the baseline and the modeled intervention. We used data  
224 from the 2010 Economic Burden of Illness in Canada (EBIC)(48), the most recent available and  
225 comprehensive national disease-specific costs study. Direct healthcare costs in EBIC 2010 are  
226 reported by diagnostic category disaggregated by age/sex groups.

227 We followed previous published methods for the estimation of direct healthcare costs for each of  
228 the modeled diseases(49) (i.e., total and by prevalence case). We prioritized alignment of WHO  
229 ICD-10(33) codes between prevalence case data with EBIC 2010 categories, as well as disease  
230 definition as closely as possible with the Global Burden of Disease study (2019)(50). Therefore,  
231 we first identified the best fitting EBIC diagnostic category by matching ICD-10 codes for each  
232 disease under study. We used the EBIC 2010 online tool to produce costs for each EBIC  
233 category by sex (male, female) and age group (0-14 years, 15-34, 35-54, 55-64, 65-74, 75+)(51).  
234 Direct healthcare costs are comprised of attributable (drug, hospital care – day surgery, hospital  
235 care – inpatient, hospital care – other ambulatory care, hospital care – outpatient – clinic, hospital  
236 care – outpatient – emergency, and physician care) and unattributable direct costs (other  
237 institutions, other professionals, capital, public health, administration, and other health  
238 spending).

239 EBIC diagnostic categories only provide disease-specific estimates for attributable direct costs,  
240 but also report total unattributable direct costs; thus, unattributable direct costs were estimated

241 and added to cost estimates per disease. The proportion of each modeled disease's share to the  
242 total attributable direct cost was estimated for each age/sex group using a method developed by  
243 Krueger et al(52). Subsequently, this proportion was applied to the total unattributable direct  
244 costs to then include these estimates in the total direct healthcare costs for each disease. Costs  
245 per disease case were then calculated by dividing estimated direct healthcare costs for each  
246 age/sex group by prevalent cases in 2010, yielding the cost per case per year. A decision was  
247 made on using prevalent cases for each disease based on their clinical pattern of exerting costs;  
248 hence, these were treated as prevalent cases. Lastly, healthcare costs were inflated to 2019  
249 Canadian Dollars (CAD), and inflation factor was estimated using the 'health care' sub-index  
250 from the Statistics Canada Consumer Price Index(53). Methods, sources, and direct healthcare  
251 costs estimations, by each modeled disease, are described in **Table 1** and **Supplementary**  
252 **Tables S4 and S5**.

### 253 *2.3 Sensitivity analysis*

254 Sensitivity analysis was conducted to examine the impact of uncertainty in the discount rate by  
255 applying 0% and 3% discount rate, as recommended by the CADTH(22). Additionally, we also  
256 used time horizons of 10 and 50 years.

### 257 *2.4 Statistical analysis*

258 The National Cancer Institute (NCI) method(54) was used to estimate Canadian adults' usual  
259 sodium intakes and distributions for all adults and by DRI age/sex group (baseline and  
260 counterfactual scenarios). The 1-part (amount only) model was used as zero consumption of  
261 sodium was <5%, as recommended by Davis et al(55), which also allowed us to stratify analysis

262 by DRI age/sex groups and to remove outliers for implausible sodium intakes. Confidence  
263 intervals and standard error were estimated using the bootstrap balanced repeated replication  
264 method (500 replicates). Additionally, we applied sample survey weights (Statistics Canada) to  
265 all analyses to ensure nationally representative estimates(35). Statistical analyses were conducted  
266 using SAS version 9.4.

267 After inputting all the required data in PRIMETIME, the model estimated the avoidable ischemic  
268 heart disease and stroke incidence cases, healthcare costs savings, and QALYs for each  
269 counterfactual scenario, by sex and each disease of interest. Uncertainty intervals (95% UI) were  
270 produced using Monte Carlo simulation at 5000 iterations to allow the epidemiological  
271 parameters in PRIMETIME to fluctuate randomly following the distributions considered in the  
272 model(24).

### 273 **3. Results**

#### 274 *Meeting sodium intake recommendations*

275 Fully meeting Health Canada's sodium reduction targets was estimated to reduce mean sodium  
276 intakes to the national sodium intake recommendations (~2,300 mg/day; 17% reduction from  
277 current levels). This reduction in sodium intake was estimated to prevent 219,490 (95% UI,  
278 73,409 – 408,630) incident cases of IHD, and 164,435 (95% UI, 56,121 – 305,770) strokes.  
279 Approximately, 63% of prevented IHD cases were estimated in males (137,188 [95% UI, 44,185  
280 – 259,658]) and 37% in females (82,303 [95% UI, 29,224 – 148,972]), and 57% of prevented  
281 strokes were estimated in males (94,522 [95% UI, 31,032 – 179,060]) and 43% in females  
282 (69,913 [95% UI, 25,088 – 126,710]). These health gains result in an overall gain of 276,185

283 QALYs (95% UI, 85,414 – 552,616), with 62% attributed to males and 38% to females. This  
284 translates into CAD\$ 4,212 million (95% UI, CAD\$ 1,303 – CAD\$ 8,206) in healthcare cost  
285 savings (69% in males, 31% in females) over the lifetime of the 2019 Canadian cohort (**Tables 3**  
286 **and 4, Figure 1 and 2**).

287 Greater health and healthcare cost gains were estimated if Canadians were to meet WHO's  
288 population-level sodium intake recommendations (2,000 mg/day) and the Adequate Intake  
289 recommendation (1,500 mg/day) (**Tables 3 and 4, Figure 1 and 2**).

#### 290 *Implementing 'high in' front-of-pack labeling regulations*

291 Sodium intake reduction through the implementation of FOPL regulations, as suggested by early  
292 evaluations of the Chilean FOPL regulations, has the potential to prevent 57,023 (95% UI,  
293 17,350 – 114,447) incident cases of IHD, and 41,794 (95% UI, 12,389 – 85,302) strokes.  
294 Approximately 64% of prevented IHD cases were estimated in males (36,323 [95% UI, 10,526 –  
295 73,593]) and 36% in females (20,701 [95% UI, 6,824 – 40,854]), and 58% of prevented strokes  
296 were estimated in males (24,443 [95% UI, 7,028 – 50,943]) and 42% in females (17,351 [95%  
297 UI, 5,361 – 34,359]). These health gains result in an overall gain of 74,499 QALYs (95% UI,  
298 21,108 – 160,246), with 63% attributed to males and 37% to females. This translates into CAD\$  
299 1,149 million (95% UI, CAD\$ 329 – CAD\$ 2,381) in healthcare cost savings (71% in males,  
300 29% in females) over the lifetime of the 2019 Canadian cohort (**Tables 3 and 4, Figure 1 and**  
301 **2**).

302 Greater health and healthcare cost gains were projected based on the criteria used by WHO to  
303 estimate FOPL cost-effectiveness and results from a FOPL systematic review and network meta-

304 analysis. An increase of 34% and 64% in all outcomes was estimated, respectively, versus the  
305 results based on evaluations of the Chilean FOPL (**Tables 3 and 4, Figure 1 and 2**).

306 Sodium intake reduction through consumer food substitution – specifically, when consumers  
307 choose food products with fewer ‘high in’ FOPL symbols – has the potential to prevent between  
308 35,930 (95% UI, 8,085 – 80,528) and 124,744 (95% UI, 40,125 – 235,643) cases of IHD, and  
309 between 26,869 (95% UI, 5,235 – 61,621) and 93,129 (95% UI, 30,296 – 176,014) strokes. This  
310 results in QALY gains ranging from 45,492 (95% UI, 10,281 – 106,579) to 157,628 (95% UI,  
311 46,701 – 320,622), and healthcare cost savings ranging from CAD\$ 695 million (95% UI, CAD\$  
312 160 – CAD\$ 1,580) to CAD\$ 2,415 million (95% UI, CAD\$ 722 – CAD\$ 4,746) over the  
313 lifetime of the 2019 Canadian cohort (**Tables 3 and 4, Figure 1 and 2**).

314 All sodium reduction strategies tested in this study were cost saving from the public healthcare  
315 system perspective. Estimated benefits were greater for males than females in all scenarios  
316 tested.

### 317 *Sensitivity analysis*

318 We examined the impact of uncertainty in the discount rate by applying discount rates of 3% and  
319 0%. When a 3% discount rate was applied to both health and healthcare cost outcomes, a  
320 decrease of 44% and 39% were observed on average for QALYs and healthcare costs,  
321 respectively, in all scenarios. Conversely, when a 0% discount rate was applied, an increase of  
322 96% and 78% were observed on average for QALYs and healthcare costs, respectively, in all  
323 scenarios (See **Supplementary Table S10**).



324 Furthermore, using time horizons of 10 and 50 years, the model predicted that 7% and 76%,  
325 respectively, of estimated lifetime healthcare cost savings would occur within those time  
326 horizons. For QALYs gained, the model estimated that 4% and 67%, respectively, of estimated  
327 lifetime gains would occur within those same time horizons (See **Supplementary Table S11**).

## 328 **4. Discussion**

329 This study estimated the potential impact of reducing sodium intake on the incidence of ischemic  
330 heart disease and stroke cases, savings in healthcare costs, and QALYs gains. Our results  
331 demonstrate that reducing sodium intakes through population-level strategies, such as  
332 implementing sodium reduction targets and ‘high in’ FOPL regulations, has the potential to  
333 improve health outcomes and reduce healthcare expenditures in Canada. This adds to current  
334 evidence, generated by simulation modeling studies, showing that sodium reduction strategies  
335 can potentially improve health outcomes and save costs to the health system, globally(29, 56-62)  
336 and in Canada(10, 19).

337 To the best of our knowledge, this is the first study estimating the potential health (QALYs) and  
338 healthcare costs of current sodium reduction initiatives in Canada. We tested ten counterfactual  
339 scenarios aiming to reduce population sodium intake. These included achieving recommended  
340 sodium intakes levels (2,000 and 1,500 mg/day); meeting sodium reduction targets for packaged  
341 foods established by Health Canada (food reformulation, 2,300 mg/day); and estimated changes  
342 in sodium intake resulting from implementing the recently approved ‘high in’ FOPL regulations.  
343 As expected, our results showed the greatest health gains and healthcare cost savings from  
344 meeting population-level sodium intake recommendations of 2,000 mg/day (441,475 QALYs;  
345 CAD\$ 6,692 million in healthcare costs savings) and 1,500 mg/day (701,592 QALYs; CAD\$

346 10,624 million in healthcare costs savings). Our study sheds light on how far Canadians are from  
347 achieving these maximum benefits with current sodium reduction policy initiatives.

348 For instance, for the policy initiatives tested in this study (i.e., meeting sodium reduction targets  
349 and implementing ‘high in’ FOPL regulations), most health and healthcare costs gains were  
350 attributed to fully meeting Health Canada’s sodium reduction targets (276,185 QALYs; CAD\$  
351 4,212 million in healthcare costs savings). Greater benefits were observed for males than  
352 females, in all scenarios tested, which could be attributed to differences in sodium consumption  
353 and CVD burden among Canadians males and females(9, 10, 63). Unfortunately, progress  
354 evaluations have shown that compliance with the voluntary sodium reduction targets has been  
355 limited, with only 14% of food categories meeting the targets by 2017(14), indicating that to  
356 meet targets by 2025(13) faster progress is needed. A robust government-led monitoring system  
357 and higher compliance from the food industry could contribute towards increasing sodium  
358 reduction progress in Canada. The consequences of not meeting established sodium reduction  
359 targets for processed foods represents an important missed opportunity to generate substantial  
360 health and healthcare costs gains in Canada.

361 Canada could benefit from other countries experiences that have implemented mandatory sodium  
362 reduction targets. For instance, South Africa’s legislation setting mandatory maximum sodium  
363 levels in foods has led to a decrease of 1.15 g/day in salt intake (~460 mg/day of sodium) in a  
364 four-year period (2015-2019). Interestingly, similar sodium reduction levels were estimated for  
365 our scenario of fully meeting sodium reduction targets(64), which indicates the feasibility of this  
366 strategy. This also highlights the importance of changing the voluntary nature of sodium  
367 reduction targets in Canada to mandatory sodium reduction targets. More recently, the WHO  
368 released the *WHO global sodium benchmarks for different food categories*(65). This set of

369 sodium reduction targets includes 18 main food categories and 97 food subcategories. Greater  
370 benefits would be expected from meeting these targets in Canada, given that for several common  
371 food categories WHO targets are more stringent than Health Canada's sodium reduction targets.  
372 In Australia, it has been estimated that meeting WHO benchmarks, as opposed to meeting  
373 Australian sodium reduction targets, could prevent or delay nearly three and a half times as many  
374 diet related NCD deaths(62).

375 The potential impact of FOPL regulations was estimated through two pathways. The first was  
376 based on recent FOPL evidence from observational and experimental studies(38-40) that  
377 estimated changes in the content of nutrients of public health concern, including sodium, in food  
378 and beverage purchases when a 'high in' FOPL was in place. Among these scenarios is one  
379 based on early evaluations of the Chilean FOPL (S4), which most likely captured consumer  
380 behavior change and initial industry-driven food reformulation. The health and healthcare cost  
381 gains estimated from this scenario represent approximately 27% of the gains estimated from  
382 meeting Health Canada's sodium reduction targets. The second pathway was based on consumer  
383 research reporting the proportion of consumers that choose or were willing to choose products  
384 with fewer 'high in' FOPL symbols(42-47), which would only capture consumer behavior  
385 change. The estimated benefits from these scenarios range from 16% to 57% of the benefits  
386 estimated from meeting Health Canada's sodium reduction targets.

387 The differences in FOPL scenarios tested are reflected in our estimates. We observed greater  
388 benefits from changes observed in food and beverage purchases in the presence of FOPL (S4-6)  
389 than from food substitution as a response of FOPL (S7-9). It is worth noting that our study  
390 focused solely on benefits from reducing sodium intake as a result of implementing FOPL in  
391 Canada. Therefore, it is expected that implementation of FOPL will result in greater health and

392 healthcare cost benefits, as it also targets other nutrients-of-concern (i.e., sugars and saturated  
393 fats) not accounted for in our estimates. For instance, a recent study from our research group  
394 estimated that 15% of diet related NCD deaths that could be averted or delayed due to  
395 implementation of FOPL in Canada were attributed to sodium(21).

396 A previous Canadian modeling study estimated potential health and healthcare cost benefits, over  
397 a 50-year time horizon, from reducing sodium intake levels by 1,500 mg/day(19). They  
398 estimated benefits of 1,021,458 QALYs and CAD\$16,805 million in healthcare cost savings(19).  
399 In comparison, the largest reduction we tested was a reduction in sodium intake of 1,258 mg/day  
400 to achieve the AI recommendations (1,500 mg/day). Under this scenario we projected benefits of  
401 471,748 QALYs and CAD\$ 8,083 million in healthcare cost savings over a 50-year time horizon.  
402 Differences likely stem from variations in the magnitude of the tested sodium reduction intake  
403 (reductions of 1500 mg/day vs. 1,258 mg/day), differences in methodology used to estimate  
404 healthcare costs, improved management of SBP in Canada, and slight reductions observed in the  
405 burden of CVDs in Canada. In the US a sodium reduction of 1,200 mg/day has been predicted to  
406 gain between 194,000 and 392,000 QALYs and save between \$10,000 to \$24,000 million in  
407 healthcare costs(66).

408 This study has limitations and strengths that need to be considered in the interpretation of our  
409 results. First, scenario modeling is an analytical technique; hence, results are as appropriate and  
410 generalizable as the data, assumptions and constraints that are applied to the mathematical  
411 model(67). To mitigate this, we used Canadian-specific and nationally representative data as  
412 inputs for the model. Additionally, our counterfactual sodium reduction intervention scenarios  
413 are based on Canadian sodium reduction targets and the most recent available evidence on the  
414 impact of FOPL regulations. We followed the perspective of the public healthcare system; hence,

415 the costs of implementing the sodium reduction interventions were not considered. Although  
416 population-wide sodium reduction interventions in Canada were estimated to cost CAD\$2.02 per  
417 person annually (Canadian population in 2019: 38 million approximately), these costs would be  
418 minimal in comparison with savings in healthcare costs(19, 68). These costs included  
419 government led industry agreements to reduce sodium in packaged foods, government  
420 monitoring of industry compliance, and public health campaigns(19, 68). We also did not  
421 consider societal gains in our modeling, such as productivity gains from preventing premature  
422 deaths or disease burden.

423 Furthermore, we focused on the potential health effects of reducing sodium intake, specifically  
424 health effects from IHD and stroke, the leading causes of death globally. However, recent studies  
425 have estimated potential effects of reducing sodium on other diseases such as chronic kidney  
426 disease and stomach cancer(58, 59, 69, 70). Therefore, our estimations of the potential benefits  
427 of reducing population-level sodium intake are conservative, considering that reducing sodium  
428 intake could also have positive effects on other diseases. Lastly, this study used data for the  
429 entire Canadian population without considering equity aspects. Future research can expand our  
430 work by examining the differential impacts of reducing sodium intake among diverse subgroups.

431 This study also has strengths to consider. Dietary sodium intake data was estimated using data  
432 from a nationally representative sample of the Canadian population (CCHS-Nutrition 2015).  
433 Surveys of this kind are usually prone to biases related to misreporting due to recall bias.  
434 Nevertheless, CCHS-Nutrition 2015 used the Automated Multiple Pass Method to reduce the  
435 impact of such reporting errors. We used the NCI method to estimate usual sodium intakes and  
436 adjusted for age, sex, dietary misreporting status, weekend/weekday, and sequence of dietary  
437 recall. For modeling we used the PRIMETIME model, a robust, validated and widely used

438 proportional multi-state lifetable model(23, 24). Strengths and limitations of the model have been  
439 previously published(24). We also conducted sensitivity analysis to examine the impact of  
440 uncertainty in the discount rate by applying 0% and 3% discount rates, as has been  
441 recommended(22). As expected, variations in discount rates, both higher and lower than our  
442 main analysis (1.5% discount rate), had a significant impact on health and healthcare cost  
443 outcomes.

444 Our findings provide evidence for policymakers and stakeholders of the potential benefits of  
445 reducing sodium intake through strategies widely discussed in Canada that target packaged  
446 foods. This is especially relevant because packaged foods are the main source of sodium intake  
447 for Canadians(9). Multicomponent strategies have proven to be more effective and are necessary  
448 for reaching the national and global sodium recommendations(11, 71). Therefore, in addition to  
449 moving from voluntary to mandatory sodium reduction targets for packaged foods and  
450 implementing ‘high in’ FOPL regulations, other initiatives should be considered for Canadians to  
451 meet population-level sodium intake recommendations (2,000 and 1,500 mg/day). These could  
452 include setting sodium reduction targets for restaurant foods, restricting marketing of foods ‘high  
453 in’ sodium, enabling healthy food environments in public settings by providing lower sodium  
454 options, regulating the digital food environment to require nutritional information, encouraging  
455 the use of low-sodium, potassium-enriched salt, and adopting approaches such as social  
456 marketing to develop behavior change communication and mass media campaigns(11, 72, 73). A  
457 combination of strategies, as has been recommended by the WHO’s *SHAKE Technical Package  
458 for Salt Reduction*(11), would be of most benefit from a public health standpoint.

## 459 **5. Conclusions**

460 Reducing population-level sodium intakes is feasible and has the potential to improve health  
461 outcomes and save healthcare costs in Canada. From the interventions tested most health and  
462 healthcare costs gains were attributed to fully meeting sodium reduction targets, which highlights  
463 the importance of changing the voluntary nature of these targets to mandatory. A combination of  
464 strategies, mandatory sodium reduction targets and implementation of the ‘high in’ FOPL  
465 symbol would be of most benefit from a public health standpoint. Thus, policymakers and  
466 stakeholders need to strengthen, and coordinate actions aimed at reducing sodium levels in the  
467 Canadian food supply. This is crucial for improving health outcomes and saving healthcare costs.  
468 Future studies could leverage this work to evaluate potential variations in effects among diverse  
469 subgroups in Canada.

470 **Conflict of interest**

471 The authors declare that the research was conducted in the absence of any commercial or  
472 financial relationships that could be construed as a potential conflict of interest.

473 **Authors' contributions**

474 NF, AJ, and MRL conceptualized the study design; NF, AJ, BAC, LC, EN and MRL interpreted  
475 the findings; NF conducted the study, wrote the original draft, and performed the statistical  
476 analysis. All authors critically reviewed and approved the final manuscript.

477 **Funding**

478 This research was funded by Canadian Institutes of Health Research (CIHR) operating grants  
479 (PJT-165858; SA2-152805; Healthy Cities Training Award). <https://cihr-irsc.gc.ca/e/193.html>.  
480 The funders had no role in study design, data collection and analysis, decision to publish, or  
481 preparation of the manuscript.

482 **Acknowledgments**

483 The authors would like to thank Professor Peter Scarborough, University of Oxford, for allowing  
484 us to use the PRIMETIME model and discussing its application; as well as current and past  
485 L'Abbe lab members who worked on various aspects of the FLIP database, especially Anthea  
486 Christoforou who worked and published data on the sodium reformulation scenario used in this  
487 manuscript. Furthermore, the authors would like to acknowledge the assistance of Arantxa  
488 Bonifaz Rosas with the collection of Canadian healthcare cost data.

489



490 **Data Availability Statement**

491 Analytic code (R) can be made available to researchers upon request to the author. *Canadian*  
492 *Community Health Survey-Nutrition 2015 Public Use Microdata File (PUMF)* data is publicly  
493 and freely available without restriction at Statistics Canada,  
494 <https://www150.statcan.gc.ca/n1/en/catalogue/82M0024X>

495 Canadian population demographics, healthcare costs and epidemiology data associated with  
496 ischemic heart disease and stroke were obtained from publicly available sources – also detailed  
497 in the main manuscript.

498 <https://www150.statcan.gc.ca/t1/tb11/en/tv.action?pid=1710000501>

499 <https://www150.statcan.gc.ca/t1/tb11/en/tv.action?pid=1310070901>

500 <https://www150.statcan.gc.ca/t1/tb11/en/tv.action?pid=1310014701>

501 <https://health-infobase.canada.ca/ccdss/data-tool/>

502 <https://cost-illness.canada.ca/custom-personnalise/national.php>

503 **Table 1.** Key data sources used for the application of the PRIMETIME Salt model in Canada  
 504

Parameter	Data source	Details	Year
Canadian population demographics	Statistics Canada: Table 17-10-0005-01 (Formerly CANSIM 051-0001)	1y age/sex groups 0–100+ years	2019
Deaths	Statistics Canada: Table: 13-10-0709-01 (Formerly CANSIM 102-0503)	5y age/sex groups 0–100+ years	2019
Disease-specific deaths	Statistics Canada: Table: 13-10-0147-01 (Formerly CANSIM 102-0529)	5y age/sex groups 0–90+ years	2019
Disease-specific prevalence	Canadian Chronic Disease Surveillance System	5y age/sex groups 20–90+ years	2019
Disease-specific incidence	Canadian Chronic Disease Surveillance System	5y age/sex groups 20–90+ years	2019
Case fatalities	Were derived from Statistics Canada estimates of incidence, prevalence, and deaths, using the <i>disbayes</i> R package.	1y age/sex groups 0–100+ years	2019
SBP estimates	Statistics Canada: Table: 13-10-0326-01 (Formerly CANSIM 117-0008)	different age/sex groups 6-79 years	2019
Sodium intake	Canadian Community Health Survey-Nutrition 2015	DRI age/sex groups 19+ years	2015
Direct healthcare costs, disease-specific	Economic Burden of Illness in Canada	different age/sex groups 0–75+ years	2010
Consumer price index	Statistics Canada: Table 18-10-0005-01 (Formerly CANSIM 326-0021)	health care sub-index	2019
Utility weights	Parameters used to estimate disease-specific and background utility weights were extracted from a UK catalogue of EQ-5D scores	disease-specific prevalence and incidence weights; and by 10y age bands	2011
Relative risks	Disease associated relative risks were derived from a systematic review and meta-analysis (Per 20 mmHg of SBP)	evidence from prospective studies; different age/sex groups <49-79+ years	2002

505 SBP, systolic blood pressure.


506 **Table 2.** Sodium reduction counterfactual scenarios

507

Counterfactual scenarios	Based on	Parameters modeled	Δ Sodium*	Δ Salt*	
<b>Meeting sodium intake recommendations</b>	S1: AI sodium intake recommendations (1,500 mg/day)	Flexner N, Christoforou A, et al (2023) (10)	Estimated sodium intakes by DRI age/sex group	- 1,258 mg/day	- 3.14 g/day
	S2: WHO sodium intake recommendations (2,000 mg/day)	Flexner N, Christoforou A, et al (2023) (10)	Estimated sodium intakes by DRI age/sex group	- 758 mg/day	- 1.89 g/day
	S3: Sodium reduction targets for packaged foods, reformulation (2,300 mg/day)	Flexner N, Christoforou A, et al (2023) (10)	Food & beverages with a sodium target	- 459 mg/day	- 1.15 g/day
<b>Implementing ‘high in’ FOPL regulations (food and beverage purchases)</b>	S4: Changes in food & beverage purchases (Chilean FOPL experience) (20)	Taillie L, et al (2021) (38)	Changes in sodium content of food & beverage purchases	- 128 mg/day	- 0.32 g/day
	S5: Based on WHO criteria to estimate cost-effectiveness of FOPL policies (20)	WHO (2022) (40)	Changes in sodium content of food & beverage purchases	- 174 mg/day	- 0.44 g/day
	S6: Based on a FOPL systematic review and network meta-analysis (20)	Song J, et al (2021) (39)	Changes in sodium content of food & beverage purchases	- 212 mg/day	- 0.53 g/day
<b>Implementing ‘high in’ FOPL regulations (food substitution)</b>	S7: Based on food substitution for 30% of CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 73 mg/day	- 0.18 g/day
	S8: Based on food substitution for 50% of CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 131 mg/day	- 0.33 g/day
	S9: Based on food substitution for 70% of CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 182 mg/day	- 0.45 g/day
	S10: Based on food substitution for all CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 259 mg/day	- 0.65 g/day


508 \*These values are overall intervention effect. Intervention effect by DRI age/sex group, as imputed in the PRIMETIME model, are detailed in Supplementary Table  
509 S3. Full details of each counterfactual scenario have been published elsewhere(10, 20, 21). We considered the potential impacts of FOPL implementation solely  
510 for changes in sodium intakes. FOPL, front-of-pack labeling; WHO, World Health Organization; AI, Adequate Intake; mg, milligram; CCHS, Canadian  
511 Community Health Survey.

512 **Figure 1.** Estimated QALY gained over the lifetime of the 2019 cohort, by sex and sodium reduction strategy



513  
 514 The potential QALYs gained were estimated using the PRIMETIME model(24), with inputs described in Table 1. Full details of each counterfactual scenario have  
 515 been published elsewhere(10, 20, 21). Sodium intake goal scenarios were based on WHO sodium intake recommendations of 2,000 mg/day and the AI  
 516 recommendations of 1,500 mg/day. The sodium target scenario was based on fully meeting Health Canada’s voluntary sodium reduction targets for packaged  
 517 foods. The FOPL–changes in F&B purchase scenarios were based on recent FOPL evidence from observational and experimental studies(38-40). The FOPL–  
 518 food substitution scenarios were based on consumer research reporting the proportion of consumers that choose or were willing to choose products with fewer  
 519 ‘high in’ FOPL symbols(42-47). We considered the potential impacts of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-pack  
 520 labeling; WHO, World Health Organization; AI, Adequate Intake; QALY, Quality-Adjusted Life Year; F&B, food and beverages.

521 **Figure 2.** Estimated healthcare cost savings (CAD\$ million) over the lifetime of the 2019 cohort, by sex and sodium reduction  
 522 strategy  
 523



524 The potential healthcare cost savings were estimated using the PRIMETIME model(24), with inputs described in Table 1. Full details of each counterfactual  
 525 scenario have been published elsewhere(10, 20, 21). Sodium intake goal scenarios were based on the AI recommendations of 1,500 mg/day and the WHO  
 526 sodium intake recommendations of 2,000 mg/day. The sodium target scenario was based on fully meeting Health Canada’s voluntary sodium reduction targets  
 527 for packaged foods. The FOPL–changes in F&B purchase scenarios were based on recent FOPL evidence from observational and experimental studies(38-40).  
 528 The FOPL–food substitution scenarios were based on consumer research reporting the proportion of consumers that choose or were willing to choose products  
 529 with fewer ‘high in’ FOPL symbols(42-47). We considered the potential impacts of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-  
 530 pack labeling; WHO, World Health Organization; AI, Adequate Intake; QALY, Quality-Adjusted Life Year; F&B, food and beverages.  
 531

532 **Table 3.** Prevented disease incident cases over the lifetime of the cohort, by sex and sodium  
533 reduction strategy

Counterfactual scenarios		IHD incidence cases	%	Stroke incidence cases	%
Meeting sodium intake recommendations	<b>S1: Meeting AI sodium intake recommendations (1,500 mg/day)</b>	<b>558,395 (191,157 – 1,032,085)</b>	100%	<b>418,281 (147,760 – 762,689)</b>	100%
	Males (95% UI)	344,273 (111,585 – 647,015)	62%	236,728 (79,646 – 439,265)	57%
	Females (95% UI)	214,123 (79,572 – 385,070)	38%	181,553 (68,114 – 323,425)	43%
	<b>S2: Meeting WHO sodium intake recommendations (2,000 mg/day)</b>	<b>350,142 (117,927 – 649,693)</b>	100%	<b>261,877 (88,387 – 481,374)</b>	100%
	Males (95% UI)	217,586 (70,367 – 410,138)	62%	149,596 (48,512 – 278,702)	57%
	Females (95% UI)	132,556 (47,561 – 239,555)	38%	112,280 (39,875 – 202,672)	43%
	<b>S3: Meeting sodium reduction targets for packaged foods (2,300 mg/day)</b>	<b>219,490 (73,409 – 408,630)</b>	100%	<b>164,435 (56,121 – 305,770)</b>	100%
	Males (95% UI)	137,188 (44,185 – 259,658)	63%	94,522 (31,032 – 179,060)	57%
	Females (95% UI)	82,303 (29,224 – 148,972)	37%	69,913 (25,088 – 126,710)	43%
FOPL – changes in food and beverage purchases	<b>S4: Changes in food &amp; beverage purchases (Chilean experience)</b>	<b>57,023 (17,350 – 114,447)</b>	100%	<b>41,794 (12,389 – 85,302)</b>	100%
	Males (95% UI)	36,323 (10,526 – 73,593)	64%	24,443 (7,028 – 50,943)	58%
	Females (95% UI)	20,701 (6,824 – 40,854)	36%	17,351 (5,361 – 34,359)	42%
	<b>S5: Based on WHO criteria to estimate cost-effectiveness of FOPL policies</b>	<b>76,555 (24,471 – 150,693)</b>	100%	<b>56,322 (18,202 – 111,634)</b>	100%
	Males (95% UI)	48,704 (14,968 – 96,967)	64%	32,914 (10,308 – 65,871)	58%
	Females (95% UI)	27,851 (9,503 – 53,726)	36%	23,409 (7,894 – 45,763)	42%
FOPL – food substitution	<b>S6: Based on a FOPL systematic review and network meta-analysis</b>	<b>93,714 (31,069 – 181,713)</b>	100%	<b>69,000 (23,030 – 135,388)</b>	100%
	Males (95% UI)	59,803 (19,070 – 117,662)	64%	40,490 (13,046 – 80,568)	59%
	Females (95% UI)	33,911 (11,999 – 64,051)	36%	28,511 (9,985 – 54,820)	41%
	<b>S7: Based on food substitution for 30% of CCHS-Nutrition 2015 adult participants</b>	<b>35,930 (8,058 – 80,528)</b>	100%	<b>26,869 (5,235 – 61,621)</b>	100%
	Males (95% UI)	22,968 (5,336 – 51,212)	64%	15,860 (3,221 – 36,350)	59%
	Females (95% UI)	12,962 (2,722 – 29,315)	36%	11,009 (2,013 – 25,271)	41%
	<b>S8: Based on food substitution for 50% of CCHS-Nutrition 2015 adult participants</b>	<b>63,013 (19,800 – 127,007)</b>	100%	<b>46,868 (14,668 – 94,881)</b>	100%
	Males (95% UI)	40,472 (12,467 – 82,378)	64%	27,767 (8,508 – 56,851)	59%
	Females (95% UI)	22,541 (7,332 – 44,628)	36%	19,101 (6,160 – 38,030)	41%
	<b>S9: Based on food substitution for 70% of CCHS-Nutrition 2015 adult participants</b>	<b>86,135 (28,713 – 166,394)</b>	100%	<b>63,961 (21,187 – 124,102)</b>	100%
Males (95% UI)	55,461 (17,911 – 108,730)	64%	37,984 (12,216 – 74,661)	59%	
Females (95% UI)	30,674 (10,802 – 57,664)	36%	25,977 (8,971 – 49,441)	41%	
<b>S10: Based on food substitution for all CCHS-Nutrition 2015 adult participants</b>	<b>124,744 (40,125 – 235,643)</b>	100%	<b>93,129 (30,296 – 176,014)</b>	100%	
Males (95% UI)	78,998 (24,224 – 151,268)	63%	54,299 (16,845 – 104,141)	58%	
Females (95% UI)	45,746 (15,901 – 84,375)	37%	38,830 (13,451 – 71,873)	42%	

534

535 The potential health impacts were estimated using the PRIMETIME model(24), with inputs described in Table 1. Full  
536 details of each counterfactual scenario have been published elsewhere(10, 20, 21). Sodium intake goal scenarios  
537 were based on the AI recommendations of 1,500 mg/day (S1) and the WHO sodium intake recommendations of  
538 2,000 mg/day (S2). The sodium target scenario (S3) was based on fully meeting Health Canada’s voluntary sodium  
539 reduction targets for packaged foods. The FOPL–changes in F&B purchase scenarios (S4-6) were based on recent  
540 FOPL evidence from observational and experimental studies(38-40). The FOPL–food substitution scenarios (S7-10)  
541 were based on consumer research reporting the proportion of consumers that choose or were willing to choose  
542 products with fewer ‘high in’ FOPL symbols(42-47). We considered the potential impacts of FOPL implementation  
543 solely for changes in sodium intakes. FOPL, front-of-pack labeling; IHD, ischemic heart disease; WHO, World  
544 Health Organization; AI, Adequate Intake; UI, Uncertainty Interval; CCHS, Canadian Community Health Survey.

545 **Table 4.** Estimated health gains and healthcare cost savings over the lifetime of the cohort, by  
546 sex and sodium reduction strategy

Counterfactual scenarios		QALY gains	%	Healthcare cost savings (CAD\$ million)	%
Meeting sodium intake recommendations	<b>S1: Meeting AI sodium intake recommendations (1,500 mg/day)</b>	<b>701,592 (225,679 – 1,393,230)</b>	100%	<b>10,624 (3,356 – 20,665)</b>	100%
	Males (95% UI)	425,297 (126,968 – 860,372)	61%	7,295 (2,183 – 14,410)	69%
	Females (95% UI)	276,295 (98,711 – 532,858)	39%	3,329 (1,173 – 6,255)	31%
	<b>S2: Meeting WHO sodium intake recommendations (2,000 mg/day)</b>	<b>441,475 (135,508 – 891,597)</b>	100%	<b>6,692 (2,092 – 13,017)</b>	100%
	Males (95% UI)	269,816 (77,889 – 555,809)	61%	4,626 (1,383 – 9,108)	69%
	Females (95% UI)	171,659 (57,619 – 335,788)	39%	2,067 (708 – 3,909)	31%
	<b>S3: Meeting sodium reduction targets for packaged foods (2,300 mg/day)</b>	<b>276,185 (85,414 – 552,616)</b>	100%	<b>4,212 (1,303 – 8,206)</b>	100%
	Males (95% UI)	169,889 (50,166 – 344,868)	62%	2,926 (868 – 5,769)	69%
	Females (95% UI)	106,296 (35,248 – 207,748)	38%	1,286 (435 – 2,437)	31%
FOPL – changes in food and beverage purchases	<b>S4: Changes in food &amp; beverage purchases (Chilean experience)</b>	<b>74,499 (21,108 – 160,246)</b>	100%	<b>1,149 (329 – 2,381)</b>	100%
	Males (95% UI)	46,889 (12,607 – 102,243)	63%	814 (220 – 1,708)	71%
	Females (95% UI)	27,609 (8,501 – 58,003)	37%	336 (109 – 673)	29%
	<b>S5: Based on WHO criteria to estimate cost-effectiveness of FOPL policies</b>	<b>99,867 (29,314 – 210,195)</b>	100%	<b>1,535 (455 – 3,119)</b>	100%
	Males (95% UI)	62,782 (17,670 – 134,336)	63%	1,085 (308 – 2,231)	71%
	Females (95% UI)	37,084 (11,644 – 75,859)	37%	449 (147 – 888)	29%
FOPL – food substitution	<b>S7: Based on food substitution for 30% of CCHS-Nutrition 2015 adult participants</b>	<b>45,492 (10,281 – 106,579)</b>	100%	<b>695 (160 – 1,580)</b>	100%
	Males (95% UI)	28,620 (6,375 – 68,250)	63%	492 (110 – 1,123)	71%
	Females (95% UI)	16,872 (3,906 – 38,329)	37%	204 (50 – 457)	29%
	<b>S8: Based on food substitution for 50% of CCHS-Nutrition 2015 adult participants</b>	<b>80,321 (23,373 – 169,543)</b>	100%	<b>1,231 (367 – 2,549)</b>	100%
Males (95% UI)	50,867 (14,373 – 108,277)	63%	875 (254 – 1,835)	71%	
Females (95% UI)	29,454 (9,001 – 61,265)	37%	356 (113 – 714)	29%	
FOPL – food substitution	<b>S9: Based on food substitution for 70% of CCHS-Nutrition 2015 adult participants</b>	<b>110,063 (34,011 – 228,868)</b>	100%	<b>1,688 (512 – 3,427)</b>	100%
	Males (95% UI)	69,860 (20,880 – 147,630)	63%	1,202 (351 – 2,468)	71%
	Females (95% UI)	40,203 (13,131 – 81,239)	37%	486 (161 – 959)	29%
	<b>S10: Based on food substitution for all CCHS-Nutrition 2015 adult participants</b>	<b>157,628 (46,701 – 320,622)</b>	100%	<b>2,415 (722 – 4,746)</b>	100%
Males (95% UI)	98,309 (27,375 – 203,349)	62%	1,696 (482 – 3,376)	70%	
Females (95% UI)	59,318 (19,326 – 117,273)	38%	719 (239 – 1,370)	30%	



547 The potential health gains and healthcare cost savings were estimated using the PRIMETIME model(24), with inputs  
548 described in Table 1. Full details of each counterfactual scenario have been published elsewhere(10, 20, 21). Sodium  
549 intake goal scenarios were based on the AI recommendations of 1,500 mg/day (S1) and the WHO sodium intake  
550 recommendations of 2,000 mg/day (S2). The sodium target scenario (S3) was based on fully meeting Health  
551 Canada’s voluntary sodium reduction targets for packaged foods. The FOPL–changes in F&B purchase scenarios  
552 (S4-6) were based on recent FOPL evidence from observational and experimental studies(38-40). The FOPL–food  
553 substitution scenarios (S7-10) were based on consumer research reporting the proportion of consumers that choose  
554 or were willing to choose products with fewer ‘high in’ FOPL symbols(42-47). We considered the potential impacts  
555 of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-pack labeling; IHD, WHO, World  
556 Health Organization; AI, Adequate Intake; UI, Uncertainty Interval; CCHS, Canadian Community Health Survey;  
557 QALY, Quality-Adjusted Life Year; CAD\$, Canadian dollars.

## 558 **References**

- 559 1. Institute for Health Metrics and Evaluation (IHME). GBD Compare Seattle, WA: IHME,  
560 University of Washington, 2019.2019 [Available from: [http://vizhub.healthdata.org/gbd-](http://vizhub.healthdata.org/gbd-compare)  
561 [compare](http://vizhub.healthdata.org/gbd-compare).
- 562 2. Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, et al. Global  
563 sodium consumption and death from cardiovascular causes. *New England Journal of Medicine*.  
564 2014;371(7):624-34.
- 565 3. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C,  
566 et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for  
567 the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A  
568 Report of the American College of Cardiology/American Heart Association Task Force on  
569 Clinical Practice Guidelines. *Journal of the American College of Cardiology*. 2018;71(19):e127-  
570 e248.
- 571 4. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al.  
572 Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD  
573 2019 study. *Journal of the American College of Cardiology*. 2020;76(25):2982-3021.
- 574 5. World Health Organization. Noncommunicable diseases country profiles 2018 2018  
575 [Available from: <https://apps.who.int/iris/handle/10665/274512>.
- 576 6. World Health Organization. Tackling NCDs: 'best buys' and other recommended  
577 interventions for the prevention and control of noncommunicable diseases 2017 [Available from:  
578 <https://apps.who.int/iris/handle/10665/259232>.
- 579 7. World Health Organization. Saving lives, spending less: a strategic response to  
580 noncommunicable diseases Geneva, Switzerland.2018 [Available from:  
581 <https://apps.who.int/iris/handle/10665/272534>.
- 582 8. World Health Organization. Salt reduction 2020 [Available from:  
583 <https://www.who.int/news-room/fact-sheets/detail/salt-reduction>.
- 584 9. Health Canada. Sodium Intake of Canadians in 2017 2018 [Available from:  
585 [https://www.canada.ca/content/dam/hc-sc/documents/services/publications/food-](https://www.canada.ca/content/dam/hc-sc/documents/services/publications/food-nutrition/sodium-intake-canadians-2017/2017-sodium-intakes-report-eng.pdf)  
586 [nutrition/sodium-intake-canadians-2017/2017-sodium-intakes-report-eng.pdf](https://www.canada.ca/content/dam/hc-sc/documents/services/publications/food-nutrition/sodium-intake-canadians-2017/2017-sodium-intakes-report-eng.pdf).
- 587 10. Flexner N, Christoforou AK, Bernstein JT, Ng AP, Yang Y, Fernandes Nilson EA, et al.  
588 Estimating Canadian sodium intakes and the health impact of meeting national and WHO  
589 recommended sodium intake levels: A macrosimulation modelling study. *PLOS ONE*.  
590 2023;18(5):e0284733.
- 591 11. World Health Organization. The SHAKE Technical Package for Salt Reduction. Geneva:  
592 WHO;2016. [Available from:  
593 <https://apps.who.int/iris/bitstream/handle/10665/250135/9789241511346-eng.pdf?sequence=1>.
- 594 12. Health Canada. Healthy Eating Strategy 2016 [Available from:  
595 [https://www.canada.ca/en/health-canada/services/publications/food-nutrition/healthy-eating-](https://www.canada.ca/en/health-canada/services/publications/food-nutrition/healthy-eating-strategy.html)  
596 [strategy.html](https://www.canada.ca/en/health-canada/services/publications/food-nutrition/healthy-eating-strategy.html).
- 597 13. Government of Canada. Voluntary sodium reduction targets for processed foods 2020-  
598 2025 2020 [Available from: [https://www.canada.ca/en/health-canada/services/food-](https://www.canada.ca/en/health-canada/services/food-nutrition/healthy-eating/sodium/sodium-reduced-targets-2020-2025.html)  
599 [nutrition/healthy-eating/sodium/sodium-reduced-targets-2020-2025.html](https://www.canada.ca/en/health-canada/services/food-nutrition/healthy-eating/sodium/sodium-reduced-targets-2020-2025.html).
- 600 14. Health Canada. Sodium Reduction in Processed Foods in Canada: An Evaluation of  
601 Progress toward Voluntary Targets from 2012 to 2016 2018 [Available from:  
602 [34](https://www.canada.ca/content/dam/hc-sc/documents/services/food-nutrition/legislation-</a></li></ol></div><div data-bbox=)

- 603 [guidelines/guidance-documents/guidance-food-industry-reducing-sodium-processed-foods-](#)  
604 [progress-report-2017/pub1-eng.pdf](#).
- 605 15. Government of Canada. Regulations Amending the Food and Drug Regulations (Nutrition  
606 Symbols, Other Labelling Provisions, Vitamin D and Hydrogenated Fats or Oils): SOR/2022-  
607 168 2022 [Available from: [https://canadagazette.gc.ca/rp-pr/p2/2022/2022-07-20/html/sor-  
609 dors168-eng.html](https://canadagazette.gc.ca/rp-pr/p2/2022/2022-07-20/html/sor-<br/>608 dors168-eng.html)].
- 609 16. Scarborough P, Harrington RA, Mizdrak A, Zhou LM, Doherty A. The preventable risk  
610 integrated ModEl and its use to estimate the health impact of public health policy scenarios.  
611 *Scientifica*. 2014;2014.
- 612 17. Webber L, Mytton OT, Briggs AD, Woodcock J, Scarborough P, McPherson K, et al.  
613 The Brighton declaration: the value of non-communicable disease modelling in population health  
614 sciences. *European journal of epidemiology*. 2014;29:867-70.
- 615 18. Hope SF, Webster J, Trieu K, Pillay A, Ieremia M, Bell C, et al. A systematic review of  
616 economic evaluations of population-based sodium reduction interventions. *PLoS One*.  
617 2017;12(3):e0173600.
- 618 19. Qureshi H. The Economic Impact of Dietary Sodium Reduction in Canada. Calgary,  
619 Canada: University of Calgary; 2017.
- 620 20. Flexner N, Ng AP, Ahmed M, Khandpur N, Acton RB, Lee JJ, et al. Estimating the  
621 dietary and health impact of implementing front-of-pack nutrition labeling in Canada: A  
622 macrosimulation modeling study. *Frontiers in Nutrition*. 2023;10.
- 623 21. Flexner N, Ahmed M, Mulligan C, Bernstein JT, Christoforou AK, Lee JJ, et al. The  
624 estimated dietary and health impact of implementing the recently approved 'high in' front-of-  
625 package nutrition symbol in Canada: a food substitution scenario modeling study. *Frontiers in*  
626 *Nutrition*. 2023;10.
- 627 22. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the  
628 economic evaluation of health technologies: Canada. Ottawa: CADTH; 2017 Mar.
- 629 23. Dötsch-Klerk M, Bruins MJ, Detzel P, Martikainen J, Nergiz-Unal R, Roodenburg AJ, et al.  
630 Modelling health and economic impact of nutrition interventions: a systematic review.  
631 *European Journal of Clinical Nutrition*. 2022;1-14.
- 632 24. Cobiac LJ, Law C, Scarborough P. PRIMETIME: an epidemiological model for informing  
633 diet and obesity policy. *medRxiv*. 2022:2022.05.18.22275284.
- 634 25. Cobiac LJ, Scarborough P, Kaur A, Rayner M. The Eatwell guide: modelling the health  
635 implications of incorporating new sugar and fibre guidelines. *PLoS One*. 2016;11(12).
- 636 26. Briggs ADM, Cobiac LJ, Wolstenholme J, Scarborough P. PRIMETIME CE: a multistate  
637 life table model for estimating the cost-effectiveness of interventions affecting diet and physical  
638 activity. *BMC Health Serv Res*. 2019;19(1):485.
- 639 27. Kent S, Aveyard P, Astbury N, Mihaylova B, Jebb SA. Is Doctor Referral to a Low-  
640 Energy Total Diet Replacement Program Cost-Effective for the Routine Treatment of Obesity?  
641 *Obesity*. 2019;27(3):391-8.
- 642 28. Mytton OT, Boyland E, Adams J, Collins B, O'Connell M, Russell SJ, et al. The  
643 potential health impact of restricting less-healthy food and beverage advertising on UK television  
644 between 05.30 and 21.00 hours: A modelling study. *PLoS medicine*. 2020;17(10):e1003212.
- 645 29. Alonso S, Tan M, Wang C, Kent S, Cobiac L, MacGregor GA, et al. Impact of the 2003  
646 to 2018 Population Salt Intake Reduction Program in England: A Modeling Study. *Hypertension*.  
647 2021;77(4):1086-94.

- 648 30. Cobiac LJ, Scarborough P. Modelling the health co-benefits of sustainable diets in the  
649 UK, France, Finland, Italy and Sweden. *European journal of clinical nutrition*. 2019;73(4):624-  
650 33.
- 651 31. Aminde LN, Phung HN, Phung D, Cobiac LJ, Veerman JL. Dietary salt reduction,  
652 prevalence of hypertension and avoidable burden of stroke in Vietnam: modelling the health and  
653 economic impacts. *Frontiers in public health*. 2021;9:682975.
- 654 32. Jackson C. Bayesian estimation of chronic disease epidemiology from incomplete data:  
655 the disbayes package 2023 [Available from:  
656 <https://chjackson.github.io/disbayes/articles/disbayes.html#data-required-by-the-bayesian-model>.  
657 33. World Health Organization. International Statistical Classification of Diseases and  
658 Related Health Problems 10th Revision 2016 [Available from:  
659 <https://icd.who.int/browse10/2016/en#/I20-I25>.  
660 34. Jackson C, Zapata-Diomedí B, Woodcock J. Bayesian multistate modelling of incomplete  
661 chronic disease burden data. *Journal of the Royal Statistical Society Series A: Statistics in*  
662 *Society*. 2023;186(1):1-19.
- 663 35. Health Canada. 2015 Canadian Community Health Survey - Nutrition. Reference Guide  
664 to Understanding and Using the Data 2017 [Available from: [https://www.canada.ca/en/health-](https://www.canada.ca/en/health-canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-community-health-survey-cchs/reference-guide-understanding-using-data-2015.html)  
665 [canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-](https://www.canada.ca/en/health-canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-community-health-survey-cchs/reference-guide-understanding-using-data-2015.html)  
666 [community-health-survey-cchs/reference-guide-understanding-using-data-2015.html](https://www.canada.ca/en/health-canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-community-health-survey-cchs/reference-guide-understanding-using-data-2015.html).  
667 36. National Academies of Sciences Engineering and Medicine. Dietary Reference Intakes  
668 Collection 2022 [Available from: [https://nap.nationalacademies.org/collection/57/dietary-](https://nap.nationalacademies.org/collection/57/dietary-reference-intakes)  
669 [reference-intakes](https://nap.nationalacademies.org/collection/57/dietary-reference-intakes).  
670 37. Bernstein JT, Christoforou AK, Flexner N, L'Abbe MR. Comparing the nutritional  
671 composition of foods and beverages in the Canadian Nutrient File to a large representative  
672 database of Canadian prepackaged foods and beverages. *PLOS ONE*. 2023;18(3):e0280028.
- 673 38. Taillie LS, Bercholz M, Popkin B, Reyes M, Colchero MA, Corvalán C. Changes in food  
674 purchases after the Chilean policies on food labelling, marketing, and sales in schools: a before  
675 and after study. *The Lancet Planetary Health*. 2021;5(8):e526-e33.
- 676 39. Song J, Brown MK, Tan M, MacGregor GA, Webster J, Campbell NR, et al. Impact of  
677 color-coded and warning nutrition labelling schemes: A systematic review and network meta-  
678 analysis. *PLoS Medicine*. 2021;18(10):e1003765.
- 679 40. World Health Organization. Technical briefing for Appendix 3 of the Global Action Plan  
680 for Non-Communicable Diseases 2022 [Available from:  
681 [https://www.who.int/teams/noncommunicable-diseases/updating-appendix-3-of-the-who-global-](https://www.who.int/teams/noncommunicable-diseases/updating-appendix-3-of-the-who-global-ncd-action-plan-2013-2030)  
682 [ncd-action-plan-2013-2030](https://www.who.int/teams/noncommunicable-diseases/updating-appendix-3-of-the-who-global-ncd-action-plan-2013-2030).  
683 41. Appelhans BM, French SA, Tangney CC, Powell LM, Wang Y. To what extent do food  
684 purchases reflect shoppers' diet quality and nutrient intake? *International Journal of Behavioral*  
685 *Nutrition and Physical Activity*. 2017;14(1):1-10.
- 686 42. Ministerio de Salud de Chile. Informe de evaluación de la implementación de la Ley  
687 sobre composición nutricional de los alimentos y su publicidad 2017 [Available from:  
688 [https://www.minsal.cl/wp-content/uploads/2017/05/Informe-Implementación-Ley-](https://www.minsal.cl/wp-content/uploads/2017/05/Informe-Implementación-Ley-20606-junio-2017-PDF.pdf)  
689 [20606-junio-2017-PDF.pdf](https://www.minsal.cl/wp-content/uploads/2017/05/Informe-Implementación-Ley-20606-junio-2017-PDF.pdf).  
690 43. Ministerio de Salud de Chile. Informe de evaluación de la implementación de la ley sobre  
691 composición nutricional de los alimentos y su publicidad 2018 [Available from:  
692 [https://www.minsal.cl/wp-content/uploads/2018/05/Informe-Implementación-Ley-20606-](https://www.minsal.cl/wp-content/uploads/2018/05/Informe-Implementación-Ley-20606-febrero-18-1.pdf)  
693 [febrero-18-1.pdf](https://www.minsal.cl/wp-content/uploads/2018/05/Informe-Implementación-Ley-20606-febrero-18-1.pdf).

- 694 44. Ministerio de Salud de Chile. Informe sobre evaluaciones de la Ley N° 20.606 sobre  
695 composicion nutricional de los alimentos y su publicidad 2021 [Available from:  
696 [https://www.minsal.cl/wp-content/uploads/2022/02/EVALUACION-LEY-DE-ALIMENTOS-  
697 oct2021.pdf](https://www.minsal.cl/wp-content/uploads/2022/02/EVALUACION-LEY-DE-ALIMENTOS-<br/>697 oct2021.pdf).  
698 45. Bromberg M, Sinai T, Keinan-Boker L, Endevelt R, Frankenthal D. Current use of  
699 nutrition facts tables and attitudes towards new red and green front-of-package labels among  
700 Israeli consumers. *International Journal of Food Sciences and Nutrition*. 2022;73(2):230-7.  
701 46. Shahrabani S. The impact of Israel’s Front-of-Package labeling reform on consumers’  
702 behavior and intentions to change dietary habits. *Israel Journal of Health Policy Research*.  
703 2021;10(1):1-11.  
704 47. Mansfield ED, Ibanez D, Chen F, Chen E, de Grandpré E. Efficacy of “High in” Nutrient  
705 Specific Front of Package Labels—A Retail Experiment with Canadians of Varying Health  
706 Literacy Levels. *Nutrients*. 2020;12(10):3199.  
707 48. Public Health Agency of Canada. Economic Burden of Illness in Canada, 2010 2018  
708 [Available from: [https://www.canada.ca/en/public-health/services/publications/science-research-  
709 data/economic-burden-illness-canada-2010.html](https://www.canada.ca/en/public-health/services/publications/science-research-<br/>709 data/economic-burden-illness-canada-2010.html).  
710 49. Jones AC. Predicting the potential health and economic impact of a sugary drink tax in  
711 Canada: a modelling study: UWSpace; 2018.  
712 50. Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2019 (GBD  
713 2019) Data Resources 2019 [Available from: <https://ghdx.healthdata.org/gbd-2019>.  
714 51. Government of Canada. Economic Burden of Illness in Canada custom report generator  
715 2010 [Available from: <https://cost-illness.canada.ca/custom-personnalise/national.php>.  
716 52. Krueger H, Krueger J, Koot J. Variation across Canada in the economic burden  
717 attributable to excess weight, tobacco smoking and physical inactivity. *Canadian journal of  
718 Public health*. 2015;106(4):e171-e7.  
719 53. Canada S. Consumer Price Index, annual average, not seasonally adjusted. Statistics  
720 Canada: Table 18-10-0005-01 (formerly CANSIM 326-0021) 2019 [Available from:  
721 <https://www150.statcan.gc.ca/t1/tbl1/en/cv.action?pid=1810000501>.  
722 54. National Cancer Institute. Usual Dietary Intakes: SAS Macros for the NCI Method 2018  
723 [Available from: <https://epi.grants.cancer.gov/diet/usualintakes/macros.html>.  
724 55. Davis KA, Gonzalez A, Loukine L, Qiao C, Sadeghpour A, Vigneault M, et al. Early  
725 experience analyzing dietary intake data from the Canadian Community Health Survey—  
726 nutrition using the National Cancer Institute (NCI) method. *Nutrients*. 2019;11(8):1908.  
727 56. Nilson EAF, Pearson-Stuttard J, Collins B, Guzman-Castillo M, Capewell S, O’Flaherty  
728 M, et al. Estimating the health and economic effects of the voluntary sodium reduction targets in  
729 Brazil: microsimulation analysis. *BMC medicine*. 2021;19(1):1-10.  
730 57. Shangquan S, Mozaffarian D, Sy S, Lee Y, Liu J, Wilde PE, et al. Health Impact and  
731 Cost-Effectiveness of Achieving the National Salt and Sugar Reduction Initiative Voluntary  
732 Sugar Reduction Targets in the United States: A Micro-Simulation Study. *Circulation*. 2021.  
733 58. Aminde LN, Wanjau MN, Cobiac LJ, Veerman JL. Estimated Impact of Achieving the  
734 Australian National Sodium Reduction Targets on Blood Pressure, Chronic Kidney Disease  
735 Burden and Healthcare Costs: A Modelling Study. *Nutrients*. 2023;15(2).  
736 59. Aminde LN, Cobiac LJ, Phung D, Phung HN, Veerman JL. Avoidable burden of stomach  
737 cancer and potential gains in healthy life years from gradual reductions in salt consumption in  
738 Vietnam, 2019–2030: A modelling study. *Public Health Nutrition*. 2023;26(3):586-97.

- 739 60. Aminde LN, Cobiac L, Veerman JL. Cost-effectiveness analysis of population salt  
740 reduction interventions to prevent cardiovascular disease in Cameroon: mathematical modelling  
741 study. *BMJ open*. 2020;10(11):e041346.
- 742 61. Trieu K, Coyle DH, Afshin A, Neal B, Marklund M, Wu JH. The estimated health impact  
743 of sodium reduction through food reformulation in Australia: A modeling study. *PLoS Medicine*.  
744 2021;18(10):e1003806.
- 745 62. Trieu K, Coyle DH, Rosewarne E, Shahid M, Yamamoto R, Nishida C, et al. Estimated  
746 Dietary and Health Impact of the World Health Organization's Global Sodium Benchmarks on  
747 Packaged Foods in Australia: a Modeling Study. *Hypertension*. 2023.
- 748 63. Pacheco C, Mullen KA, Coutinho T, Jaffer S, Parry M, Van Spall HGC, et al. The  
749 Canadian Women's Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and  
750 Management of Cardiovascular Disease in Women - Chapter 5: Sex- and Gender-Unique  
751 Manifestations of Cardiovascular Disease. *CJC Open*. 2022;4(3):243-62.
- 752 64. Charlton KE, Corso B, Ware L, Schutte AE, Wepener L, Minicuci N, et al. Effect of  
753 South Africa's interim mandatory salt reduction programme on urinary sodium excretion and  
754 blood pressure. *Preventive medicine reports*. 2021;23:101469.
- 755 65. World Health Organization. WHO global sodium benchmarks for different food  
756 categories. Geneva: WHO;2021. [Available from:  
757 <https://www.who.int/publications/i/item/9789240025097>.
- 758 66. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ,  
759 et al. Projected effect of dietary salt reductions on future cardiovascular disease. *New England*  
760 *Journal of Medicine*. 2010;362(7):590-9.
- 761 67. Grieger JA, Johnson BJ, Wycherley TP, Golley RK. Evaluation of Simulation Models  
762 that Estimate the Effect of Dietary Strategies on Nutritional Intake: A Systematic Review. *The*  
763 *Journal of Nutrition*. 2017;147(5):908-31.
- 764 68. Webb M, Fahimi S, Singh GM, Khatibzadeh S, Micha R, Powles J, et al. Cost  
765 effectiveness of a government supported policy strategy to decrease sodium intake: global  
766 analysis across 183 nations. *Bmj*. 2017;356.
- 767 69. Kim J, Oh A, Truong H, Laszkowska M, Camargo MC, Abrams J, et al. Low sodium diet  
768 for gastric cancer prevention in the United States: Results of a Markov model. *Cancer Medicine*.  
769 2020.
- 770 70. Kypridemos C, Guzman-Castillo M, Hyseni L, Hickey GL, Bandosz P, Buchan I, et al.  
771 Estimated reductions in cardiovascular and gastric cancer disease burden through salt policies in  
772 England: an IMPACTNCD microsimulation study. *BMJ open*. 2017;7(1):e013791.
- 773 71. Park H-K, Lee Y, Kang B-W, Kwon K-i, Kim J-W, Kwon O-S, et al. Progress on sodium  
774 reduction in South Korea. *BMJ Global Health*. 2020;5(5):e002028.
- 775 72. Arcand J, Campbell NR. Dietary sodium reduction in Canada: more action is needed to  
776 reach the 2025 global targets. *CMAJ*. 2022;194(10):E387-E8.
- 777 73. Greer RC, Marklund M, Anderson CA, Cobb LK, Dalcin AT, Henry M, et al. Potassium-  
778 enriched salt substitutes as a means to lower blood pressure: benefits and risks. *Hypertension*.  
779 2020;75(2):266-74.

780